VLON News and Press, Vallon Pharmaceuticals Inc. From 04/13/21

Vallon Pharmaceuticals (VLON) provides a clinical program update for its lead program, ADAIR, a abuse-deterrent formulation of immediate-release ((IR)) dextroamphetamine currently in development for the treatment of attention deficit hyperactivity disorder ((ADHD)) and narcolepsy. “Our...

- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021 - Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines in the treatment of ADHD, a ~$9 billion U.S. market 1 PHILADELPHIA, P...

SOS (SOS) +36%.Titan Medical (TMDI) +25%.CBAK Energy Technology (CBAT) +21%.Altimeter Growth (AGCUU) +18%.CA Healthcare Acquisition (CAHCU) +16%.TransMedics (TMDX) +16%. as FDA Advisory Panel has issued a favorable vote in support of approval of the OCS Heart System.Altimeter Growth (AGC...

Vallon Pharmaceuticals (VLON): FY net loss of ~$4.8MCash and cash equivalents of ~$109KPress Release For further details see: Vallon Pharmaceuticals reports FY results

- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market 1 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple drugs an...

The following slide deck was published by Vallon Pharmaceuticals, Inc. in conjunction with this event. For further details see: Vallon Pharmaceuticals (VLON) Investor Presentation - Slideshow